RE: Undervalued23 Nov 2024 15:02
Earlier this week announced an expanded partnership between its subsidiary, Imaging Biometrics, and GE Healthcare. The agreement will streamline the distribution of IB Neuro and IB Delta T1 platforms, which assist in assessing and treating brain tumours.
The tools, according to the company, address key challenges like differentiating between true progression and pseudo-progression in MRIs.
Chief executive Michael Schmainda highlighted that the agreement introduces a per-scanner pricing model, expected to ease sales efforts and boost adoption. He called the partnership a potential "step change" for the company heading into 2025.